- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Hakan Kaya, MD | Authors
Selinexor: Clinical Pearls for Current and Future Use in R/R MM
October 27, 2022
Dr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.
Adverse Event Management and Dosing Strategies for Selinexor
October 20, 2022
Two experienced clinicians share their thoughts on the safety of selinexor, including how they optimize dosing to prioritize patient comfort.
Clinical Implications: Selinexor, Carfilzomib, and Dexamethasone in R/R MM
October 20, 2022
Dr Mikhael and Dr Kaya discuss the clinical implications and share their thoughts on the use of selinexor, carfilzomib and dexamethasone in patients with R/R MM.
Trial Data Review: Selinexor, Carfilzomib, and Dexamethasone in R/R MM
October 13, 2022
Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.
Selinexor: Rationale for Use in R/R MM Patients
October 13, 2022
Joseph Mikhael, MD, provides a brief overview of the relapsed/refractory multiple myeloma landscape and explains the mechanism of action of selinexor.